Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MONO-OLA1: olaparib maintenance after first-line platinum response in BRCA-wild-type advanced ovarian cancer
CTR20211622Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of olaparib in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by AstraZeneca. Started Sep 2021; status: completed.
02
Drugs
olaparib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on CTR20211622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211622.